Strategic partnerships Clonexpress offers patient-specific differentiated cell lines and custom cell line development from client samples, presenting a strong opportunity for collaboration with pharmaceutical companies and biotech firms seeking bespoke models for drug discovery, toxicity testing, and personalized medicine.

Cancer drug discovery The company claims a novel growth control mechanism in various cancers not present in normal cells, along with a sensitive assay for target identification, signaling potential partnerships or licensing deals with oncology companies focused on novel cancer therapeutics and metastasis inhibitors.

CNS and neuro models Available human CNS primary cells and differentiated neural cells including dopaminergic neurons and microglia enable vendors to enhance CNS disease pipelines, neurotoxicity screening, and preclinical testing with human-relevant models.

Platform licensing A pipeline of organ-specific cell lines such as pancreatic beta cells, hepatocytes, and microglia ready for licensing or purchase offers near-term revenue opportunities with drug discovery and toxicology service providers.

Funding and partnerships With active funding interest and a scalable tech stack, Clonexpress can attract research partnerships or co-development funding to accelerate cancer cure initiatives and expand its cell-line catalog for broader commercial use.